Background
Methods
Study population
Assessments
Statistical analyses
Results
0.3 < TSH ≤ 3.0 mIU/L | TSH ≤ 0.3 mIU/L | TSH > 3.0 mIU/L | |
---|---|---|---|
(n = 3877) | (n = 200) | (n = 107) | |
Age; years
| 52 (41; 63) | 57 (47; 68) | 48 (37; 58) |
Males
| 1949 (50.3%) | 85 (42.5%) | 40 (37.4%) |
BMI; kg/m
2
| 27.3 (24.5; 30.6) | 27.7 (24.3; 31.0) | 26.9 (23.6; 30.0) |
Physical activity
| 1986 (51.2%) | 86 (43.0%) | 61 (57.0%) |
Former smokers
| 1395 (36.0%) | 91 (45.5%) | 35 (32.7%) |
Current smokers
| 861 (22.2%) | 33 (16.5%) | 23 (21.5%) |
Systolic blood pressure, mmHg
| 128 (116; 140) | 127 (114; 140) | 124 (113; 137) |
Diastolic blood pressure, mmHg
| 78 (72; 85) | 79 (72; 85) | 78 (72; 85) |
Beta blocker use
| 862 (22.2%) | 58 (29.0%) | 22 (20.6%) |
Thyroid medication use
| 363 (9.4%) | 59 (29.5%) | 24 (22.4%) |
Education
| |||
- < 10 years
| 900 (23.2%) | 69 (34.5%) | 12 (11.2%) |
- = 10 years
| 1947 (50.2%) | 96 (48.0%) | 57 (53.3%) |
- > 10 years
| 1029 (26.6%) | 35 (17.5%) | 38 (37.5%) |
FEV
1
; l
| 3.2 (2.6; 3.8) | 3.0 (2.5; 3.6) | 3.3 (2.7; 3.8) |
FVC; l
| 4.0 (3.3; 4.8) | 3.6 (3.0; 4.4) | 4.0 (3.3; 4.7) |
FEV
1
/FVC; %
| 81.8 (77.5; 85.8) | 82.6 (78.4; 86.6) | 81.4 (77.8; 85.3) |
peakVO
2
; ml/min
| 1900 (1500; 2400) | 1703 (1450; 2092) | 1905 (1507; 2450) |
VO
2
@AT; ml/min
| 1000 (850; 1200) | 975 (800; 1175) | 950 (850; 1200) |
O
2
HR; ml/beat
| 12.8 (10.4; 15.6) | 12.0 (10.5; 15.0) | 12.4 (9.5; 14.9) |
V
E
vs. VCO
2
slope
| 26 (24; 29) | 26 (24; 29) | 26 (24; 29) |
Maximum power; watt
| 148 (116; 196) | 132 (116; 164) | 148 (116; 180) |
Exercise duration; minutes
| 9.1 (7.2; 11.4) | 8.1 (6.4; 10.1) | 9.1 (7.2; 11.1) |
Serum TSH levels and lung function
Model 1 | Model 2 | Model 3 | ||
---|---|---|---|---|
TSH full range | TSH < 0.3#
| TSH > =3#
| TSH in the reference range | |
β (95%-CI) | β (95%-CI) | β (95%-CI) | β (95%-CI) | |
FEV
1
; l
| -0.01 (-0.04; 0.01) | 0.06 (-0.06; 0.17) | -0.06 (-0.14; 0.02) | 0.01 (-0.03; 0.04) |
FVC; l
| -0.003 (-0.034; 0.028) | 0.03 (-0.10; 0.17) | -0.08 (-0.21; 0.04) | 0.02 (-0.03; 0.06) |
FEV
1
/FVC; %
| -0.35* (-0.65; -0.06) | -0.06 (-1.23; 1.12) | -0.78 (-2.02; 0.47) | -0.48* (-0.91; -0.04) |
peakVO
2
; ml/min
| 1.2 (-18.1; 20.4) | 19.2 (-46.4; 84.8) | 3.0 (-98.5; 104.5) | 12.9 (-15.4; 41.3) |
VO
2
@AT; ml/min
| -4.7 (-14.8; 5.5) | 14.0 (-19.3; 47.4) | -9.3 (-52.0; 33.5) | -4.2 (-18.2; 9.9) |
O
2
HR; ml/beat
| -0.11* (-0.22; -0.01) | 0.33 (-0.14; 0.81) | -0.31 (-0.88; 0.26) | -0.08 (-0.25; 0.08) |
V
E
vs. VCO
2
slope
| 0.11 (-0.06; 0.29) | -0.44 (-1.08; 0.19) | 0.05 (-0.69; 0.79) | 0.21 (-0.05; 0.46) |
Maximum power; watt
| 1.3 (-0.1; 2.7) | 0.1 (-5.7; 6.0) | -0.4 (-11.1; 10.3) | 1.9 (-0.1; 3.9) |
Exercise duration; minutes
| 0.02 (-0.08; 0.12) | 0.02 (-0.33; 0.37) | -0.16 (-0.62; 0.29) | 0.07 (-0.07; 0.20) |
First quintile#
| Second quintile#
| Fourth quintile#
| Fifth quintile#
| |
---|---|---|---|---|
(0 – 0.5745 mIU/L) | (0.5745 – 0.839 mIU/L) | (1.14 – 1.59 mIU/L) | (1.59 – 10.00 mIU/L) | |
β (95%-CI) | β (95%-CI) | β (95%-CI) | β (95%-CI) | |
FEV
1
; l
| 0.00 (-0.06; 0.07) | 0.02 (-0.05; 0.08) | -0.01 (-0.07; 0.05) | 0.01 (-0.05; 0.07) |
FVC; l
| -0.01 (-0.08; 0.06) | -0.01 (-0.08; 0.07) | -0.002 (-0.073; 0.069) | 0.005 (-0.073; 0.083) |
FEV
1
/FVC; %
| 0.31 (-0.38; 0.99) | -0.02 (-0.75; 0.71) | -0.14 (-0.80; 0.52) | -0.45 (-1.13; 0.24) |
peakVO
2
; ml/min
| -32.3 (-73.1; 8.5) | -48.5* (-89.2: -7.9) | -35.3 (-79.8; 9.3) | -16.6 (-60.5; 27.4) |
VO
2
@AT; ml/min
| 2.4 (-21.8; 26.6) | -3.7 (-28.3; 20.9) | -11.1 (-34.5; 12.4) | -8.2 (-30.7; 14.3) |
O
2
HR; ml/beat
| -0.06 (-0.35; 0.24) | -0.25 (-0.53; 0.02) | -0.28 (-0.56; 0.01) | -0.32* (-0.59; -0.05) |
V
E
vs. VCO
2
slope
| -0.20 (0.66; 0.27) | -0.24 (-0.71; 0.23) | 0.20 (-0.23; 0.64) | 0.04 (-0.40; 0.48) |
Maximum power; watt
| -3.7* (-7.1; -0.3) | -3.1 (-6.7; 0.5) | -2.7 (-6.0; 0.6) | 0.2 (-3.2; 3.5) |
Exercise duration; minutes
| -0.22* (-0.41; -0.03) | -0.15 (-0.35; 0.04) | -0.18 (-0.39; 0.03) | -0.07 (-0.29; 0.15) |